Similar to the results derived from the whole ABC treatment history, the relationship between TP53 mutation evolutionary pattern and OS remained statistically significant when we restricted the time within four lines of treatment (P = 0.02, Fig. 5B), suggesting that newly identified TP53 mutation was a negative biomarker for ABC patients' OS. The gene discussed is TP53; the disease is aneurysmal bone cyst.